Articles relating to COVID-19 including safety tips, research updates, and vaccine information.

Lilly reports positive data from Alzheimer’s disease treatment trial

Eli Lilly and Company has reported that data from Phase II TRAILBLAZER-ALZ study of its investigational antibody, donanemab, showed a significant slowing of decline in patients with early symptomatic Alzheimer’s disease. Donanemab targets a modified form of beta-amyloid called N3pG. The randomised, placebo-controlled, double-blind, multi-centre study enrolled 272 patients to analyse the safety, tolerability and…

Teva and MedinCell report positive data from schizophrenia trial

Teva Pharmaceuticals and MedinCell have reported positive results from the Phase III TV46000-CNS-30072 the Risperidone Subcutaneous Extended-Release Study (RISE study) of investigational TV-46000/mdc-IRM for treating patients with schizophrenia. TV-46000/mdc-IRM or extended-release subcutaneous risperidone injection is a once-monthly or once-every-two-months atypical antipsychotic risperidone formulation. A chronic, progressive and severely debilitating mental disorder, Schizophrenia affects how a…